Senior Robotic Startup Specialist

"Success will be measured by access": health leaders advocate equitable care for acute stroke during UN General Assembly Week. 9 October 2026 Government officials, global health leaders, clinicians, patient advocates, professional societies and industry partners recently gathered during United Nations (UN) General Assembly Week (18-28 September 2026, New York, USA) for a meeting titled, 'From resolution to action: investing in acute stroke care', which focused on translating global commitments on stroke into concrete improvements in prevention, acute treatment, rehabilitation, and access to care. The 22 September reception was convened through the Society of Vascular and Interventional Neurology's (SVIN) Mission Thrombectomy in partnership with the Business Council for International Understanding (BCIU), Philips, and Medtronic Neurovascular. The event brought together representatives from international cardiovascular, stroke, neurointerventional and neurosurgical organisations, including the American Heart Association (AHA), World Stroke Organization (WSO), World Federation of Interventional and Therapeutic Neuroradiology (WFITN), Society of NeuroInterventional Surgery (SNIS), and International Society for Global Neurosurgery (ISGNS), alongside ministries of health and other global health stakeholders. Together, these entities brought perspectives spanning public health, stroke systems, neurointervention, global neurosurgery, policy and implementation, as noted in an SVIN press release. The release adds that this gathering came at "a pivotal moment for global stroke policy"; WHA79.10, adopted by the World Health Assembly in May 2026, represents a "landmark global commitment" to addressing stroke comprehensively, covering prevention, acute care, rehabilitation, and health-system readiness. WHA79.10 was championed by the Egyptian Ministry of Health and Population with support from the Global Stroke Action Coalition (GSAC) - which comprises organisations and industry leaders dedicated to advancing stroke prevention, treatment, rehabilitation, and access to care worldwide. The resolution represents an "important example" of how governments, professional organisations, patient advocates and industry "can work together to elevate stroke on the global health agenda", the SVIN release also states. Debates during UN General Assembly Week Discussions centred on a fundamental challenge: scientific advances have made highly effective stroke treatments possible, including mechanical thrombectomy for large vessel occlusion (LVO), but millions of eligible patients worldwide still cannot access these treatments in a timely manner. The conversation was opened by Fawaz Al-Mufti (New York Medical College, New York, USA), global chair of SVIN's Mission Thrombectomy, who shared 'the clinical and economic case for acute stroke treatment', highlighting the "extraordinary effectiveness" of mechanical thrombectomy for eligible patients with LVO stroke. Drawing on global data and an economic analysis spanning six countries, Al-Mufti emphasised that investing in access to thrombectomy can represent a fraction of the societal cost associated with stroke-related disability. "We are already paying for stroke," he commented. "The question is whether we choose to pay for recovery today or disability for years to come. A timely thrombectomy can offset a lifetime of disability and its associated costs. We need to stop viewing thrombectomy simply as a procedural expense and recognise access to effective stroke treatment as an investment in people, families, and national capacity." The patient perspective was then brought into focus by Margaret O'Neil Wheeler, who shared "a moving account of resilience and fortitude" following an LVO stroke. Accompanied by her husband, whose prompt recognition and action helped get her to lifesaving care in time, Wheeler was reunited at the event with Al-Mufti - who performed her emergency thrombectomy at Westchester Medical Center (New York, USA). Their reunion offered a "powerful reminder" of what timely access to advanced stroke care can mean: not simply survival, but recovery, independence, and the opportunity to return to life after stroke. Dileep Yavagal (University of Miami, Coral Gables, USA), founder and global chair emeritus of SVIN's Mission Thrombectomy, followed this with a presentation titled, 'From global advocacy to global action'. Yavagal described stroke as a "long-neglected pandemic" and emphasised that solving the global access gap requires more than simply building additional thrombectomy centres. Sustainable systems require public and prehospital education, government advocacy, technology, financing, trained teams, and implementation strategies tailored to individual countries, he added. "We have crossed the scientific frontier - we know thrombectomy can profoundly alter the course of a devastating stroke," Yavagal commented. "The frontier before us now is access." Clinician, industry and health-policy voices "Stroke does not respect borders, and access to lifesaving treatment should not be determined by where a patient lives," stated SVIN president Santiago Ortega-Gutierrez (University of Iowa, Iowa City, USA). "The science is clear, the therapies exist, and the global community has recognised stroke as an urgent health priority. Our responsibility now is to turn that recognition into action. Through Mission Thrombectomy, SVIN is committed to measurable progress in access, treatment, and recovery, with the goal that every eligible patient has a meaningful opportunity to survive stroke without preventable disability." "Recognition is important, but ultimately our success will be measured by access," added Mission Thrombectomy vice-chair Kaiz Asif (Endeavor Health, Chicago, USA). "Our goal is to translate this global momentum into a simple reality: that more patients, regardless of where they live, can reach lifesaving thrombectomy in time." "The science has given us the ability to dramatically change the outcome of a devastating stroke. The next challenge is ensuring that this opportunity is not defined by geography or resources. That will require sustained collaboration among clinicians, health systems, governments and communities to translate what we know into meaningful access for patients worldwide," commented SVIN president-elect Robin Novakovic-White (UT Southwestern Medical Center, Dallas, USA). The proceedings during the UN's General Assembly Week also aw industry partners underscore the fact that innovation must be accompanied by the systems required to deliver treatment. "Innovation alone is not enough," said Signe Haughton, senior director of medical, government and societal affairs, and chief of staff, at Medtronic Neurovascular. "Devices and therapies make a meaningful difference only when patients can reach the right facility, receive timely diagnosis, and be treated by trained teams within an integrated system of care." "For people experiencing stroke, every minute matters," added Felipe Basso, chief executive officer, Latin America, Philips. "Better-connected data, technologies and clinical workflows can help healthcare professionals make timely decisions, support rapid diagnosis and appropriate treatment, and expand access to the right care when patients need it most." Finally, Mohamed Fawzi - radiology advisor to the minister of health and population in the Arab Republic of Egypt's Ministry of Health and Population - provided a country-specific perspective on building a national stroke system. Egypt's progress includes 206 stroke units and centres - 58 certified through the General Authority for Healthcare Accreditation and Regulation (GAHAR) - free thrombolysis, reimbursement for thrombectomy, approval of tenecteplase, and a prehospital hotline linking approximately 100 hospitals. A national electronic stroke registry is also being launched, with plans to expand the network to 440 units, strengthen certification, establish a national rehabilitation pathway, and publish national treatment rates and treatment times. According to the SVIN's press release, the message emerging from the convening was clear: a resolution creates momentum; implementation is what changes outcomes for patients. "The science exists. The therapies exist. The opportunity now is to build the systems that ensure every eligible patient - regardless of geography or resources - can reach lifesaving stroke treatment in time," the release adds.

Barclays upgrades Medtronic (NYSE:MDT) to "Hold" October 8, 2026 Key points. * Barclays upgraded Medtronic to "Hold", adding to a mixed analyst outlook. Despite the upgrade, consensus remains "Moderate Buy," with 18 Buy ratings, 10 Holds, and an average price target of $102.92. * Medtronic shares opened at $85.51, down 1.8%, with a market capitalization of approximately $109.4 billion. The stock remains below its 52-week high of $106.33. * The company recently exceeded quarterly expectations, reporting $1.45 in adjusted EPS versus the $1.39 consensus and revenue of $9.76 billion versus estimates of $9.55 billion. Institutional investors own approximately 82.1% of the shares. * Interested in Medtronic? Here are five stocks we like better. Medtronic (NYSE:MDT - Get Free Report) was upgraded by Barclays to a "hold" rating in a report issued on Wednesday, Zacks reports. MDT has been the topic of several other research reports. Wells Fargo & Company increased their price target on shares of Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 2nd. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $118.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Truist Financial reissued a "hold" rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Piper Sandler restated a "neutral" rating on shares of Medtronic in a report on Monday, August 10th. Finally, Wall Street Zen upgraded Medtronic from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Eighteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $102.92. Medtronic trading down 1.8%. Shares of NYSE MDT opened at $85.51 on Wednesday. The stock has a market cap of $109.38 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.98 and a beta of 0.55. The business has a 50 day simple moving average of $90.18 and a 200 day simple moving average of $84.75. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Discover more Financial News Subscription Live News Feed Stock Profit Calculator Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company's revenue for the quarter was up 13.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts predict that Medtronic will post 5.98 earnings per share for the current fiscal year. Insiders place their bets. In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares of the company's stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is currently owned by corporate insiders. Institutional investors weigh in on Medtronic. Several hedge funds and other institutional investors have recently made changes to their positions in MDT. BlackRock Inc. increased its position in Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company's stock worth $8,919,846,000 after buying an additional 838,220 shares during the period. State Street Corp grew its stake in shares of Medtronic by 2.0% in the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company's stock worth $5,966,780,000 after acquiring an additional 1,199,621 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company's stock worth $2,254,200,000 after acquiring an additional 1,343,220 shares during the last quarter. First Eagle Investment Management LLC increased its position in Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company's stock worth $1,078,321,000 after acquiring an additional 3,739,288 shares during the period. Finally, WCM Investment Management LLC bought a new position in Medtronic during the first quarter worth $965,922,000. 82.06% of the stock is owned by institutional investors and hedge funds. Medtronic news roundup. Here are the key news stories impacting Medtronic this week: * Medtronic finalized an exchange ratio of 4.5939 MiniMed shares for each Medtronic ordinary share accepted in the split-off. The company will offer up to 225.4 million MiniMed shares and may exchange an additional 27.45 million shares if the offer is oversubscribed. The transaction could sharpen Medtronic's focus on medical devices while giving shareholders direct exposure to MiniMed. * Medtronic appointed Felicia Kurz as vice president and general manager of its cardiac ablation business. The move comes as demand for its pulsed-field ablation products supports strong electrophysiology growth, reinforcing investor confidence in one of the company's faster-growing businesses. * The American Medical Association granted permanent Category I CPT codes for Medtronic's Altaviva tibial neuromodulation implant and Symplicity Spyral renal denervation system. More established reimbursement may improve physician adoption and support future revenue growth. * Medtronic's FY2026 impact report said the company's technologies served more than 82 million patients worldwide. The report highlights the company's scale and social impact but offers limited immediate financial guidance. * The MiniMed split-off creates near-term uncertainty over Medtronic's share count, ownership structure and valuation. Investors may also be repositioning around the exchange ratio, contributing to elevated trading activity and pressure on MDT while the transaction is completed. Medtronic company profile. Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management. The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies. Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Medtronic, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list. While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps. Continue following MarketBeat

Medtronic: presents new nocturia data for the AltavivaTM device, announces national principal investigator for the ENDURANCE study. Published on 10/06/2026 at 05:04 pm EDT At 47th AUGS Annual Scientific Meeting, Medtronic advances AltavivaTM clinical program with 24-month exploratory findings from TITAN 2 showing sustained reductions in nightly nocturia episodes and announces partnership to advance patient awareness of pelvic floor disorders Medtronic the global leader in healthcare technology today announced new updates, including clinical evidence, for the Altaviva(TM) implantable tibial neuromodulation device at AUGS 2026, reinforcing [...] Attachments * Original document * Permalink Disclaimer Medtronic plc published this content on October 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 06, 2026 at 21:03 UTC. (C) Publicnow - 2026